Revisiting the WHO entity "myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRA, PDGFRB or FGFR1, or with PCM1-JAK2" in 74 patients: lack of eosinophilia and presence of monocytosis

被引：0
|
作者：
Steiner, L. [1 ]
Schwaab, J. [1 ]
Naumann, N. [1 ]
Jahwar, M. [1 ]
Kreil, S. [1 ]
Haferlach, T. [2 ]
Fabarius, A. [1 ]
Hofmann, W. -K. [1 ]
Cross, N. C. P. [3 ,4 ]
Reiter, A. [1 ]
Metzgeroth, G. [1 ]
机构：
[1] Univ Med Mannheim, Med Klin 3, Hamatol & Onkol, Mannheim, Germany
[2] Munchner Leukamielab, Munich, Germany
[3] Wessex Reg Genet Lab, Salisbury, Wilts, England
[4] Univ Southampton, Fac Med, Southampton, Hants, England
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2020年 / 43卷 / SUPPL 4期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
215
引用
收藏
页码：80 / 80
页数：1
相关论文
共 35 条
  • [31] A Phase 2 Study of Pemigatinib (FIGHT-203; INCB054828) in Patients With Myeloid/Lymphoid Neoplasms With Fibroblast Growth Factor Receptor 1 (FGFR1) Gene Rearrangement
    Vannucchi, Alessandro M.
    Patel, Jay L.
    Shomali, William E.
    George, Tracy I.
    Reiter, Andreas
    Rambaldi, Alessandro
    Oh, Stephen
    Usuki, Kensuke
    Harrison, Claire N.
    Veronese, Maria Luisa
    Gilmartin, Aidan
    Zhen, Huiling
    Verstovsek, Srdan
    Oliveira, Natalia
    Gotlib, Jason
    Kiladjian, Jean-Jacques
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S430 - S431
  • [32] Phase 2, open-label, multicenter study to evaluate the efficacy and safety of INCB054828 in patients with myeloid/lymphoid neoplasms with fibroblast growth factor receptor 1 (FGFR1) rearrangement
    Verstovsek, Srdan
    Rambaldi, Alessandro
    Asatiani, Ekaterine
    Lihou, Christine F.
    Zhen, Huiling
    Hochhaus, Andreas
    CANCER RESEARCH, 2017, 77
  • [33] Phase 2, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Patients with Myeloid/Lymphoid Neoplasms with Fibroblast Growth Factor Receptor 1 (FGFR1) Rearrangement
    Verstovsek, Srdan
    Rambaldi, Alessandro
    Lihou, Christine
    Zhen, Huiling
    Hochhaus, Andreas
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S350 - S351
  • [34] FIGHT-203, an Ongoing Phase 2 Study of Pemigatinib in Patients With Myeloid/Lymphoid Neoplasms (MLNs) With Fibroblast Growth Factor Receptor 1 (FGFR1) Rearrangement (MLNFGFR1): A Focus on Centrally Reviewed Clinical and Cytogenetic Responses in Previously Treated Patients
    Verstovsek, Srdan
    Gotlib, Jason
    Vannucchi, Alessandro M.
    Rambaldi, Alessandro
    Reiter, Andreas
    Shomali, William
    George, Tracy, I
    Patel, Jay L.
    Colucci, Philomena
    Zhen, Huiling
    Oliveira, Natalia
    Kiladjian, Jean-Jacques
    BLOOD, 2022, 140 : 3980 - 3982
  • [35] Interim Results from Fight-203, a Phase 2, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Pemigatinib (INCB054828) in Patients with Myeloid/Lymphoid Neoplasms with Rearrangement of Fibroblast Growth Factor Receptor 1 (FGFR1)
    Verstovsek, Srdan
    Vannucchi, Alessandro M.
    Rambaldi, Alessandro
    Gotlib, Jason R.
    Mead, Adam J.
    Hochhaus, Andreas
    Kiladjian, Jean-Jacques
    Hernandez Boluda, Juan Carlos
    Asatiani, Ekaterine
    Lihou, Christine
    Zhen, Huiling
    Reiter, Andreas
    BLOOD, 2018, 132
1234